Monika Ayten , Nundehui Díaz-Lezama , Hanaa Ghanawi , Felia C. Haffelder , Jacqueline Kajtna , Tobias Straub , Marco Borso , Axel Imhof , Stefanie M. Hauck , Susanne F. Koch
{"title":"Pde6bSTOP/STOP 视网膜色素变性小鼠模型获救后的代谢可塑性。","authors":"Monika Ayten , Nundehui Díaz-Lezama , Hanaa Ghanawi , Felia C. Haffelder , Jacqueline Kajtna , Tobias Straub , Marco Borso , Axel Imhof , Stefanie M. Hauck , Susanne F. Koch","doi":"10.1016/j.molmet.2024.101994","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Retinitis pigmentosa (RP) is a hereditary retinal disease characterized by progressive photoreceptor degeneration, leading to vision loss. The best hope for a cure for RP lies in gene therapy. However, given that RP patients are most often diagnosed in the midst of ongoing photoreceptor degeneration, it is unknown how the retinal proteome changes as RP disease progresses, and which changes can be prevented, halted, or reversed by gene therapy.</p></div><div><h3>Methods</h3><p>Here, we used a <em>Pde6b</em>-deficient RP gene therapy mouse model and performed untargeted proteomic analysis to identify changes in protein expression during degeneration and after treatment.</p></div><div><h3>Results</h3><p>We demonstrated that <em>Pde6b</em> gene restoration led to a novel form of homeostatic plasticity in rod phototransduction which functionally compensates for the decreased number of rods. By profiling protein levels of metabolic genes and measuring metabolites, we observed an upregulation of proteins associated with oxidative phosphorylation in mutant and treated photoreceptors.</p></div><div><h3>Conclusion</h3><p>In conclusion, the metabolic demands of the retina differ in our <em>Pde6b</em>-deficient RP mouse model and are not rescued by gene therapy treatment. These findings provide novel insights into features of both RP disease progression and long-term rescue with gene therapy.</p></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"88 ","pages":"Article 101994"},"PeriodicalIF":7.0000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221287782400125X/pdfft?md5=6010579f47431b45363c3e5b7663bbf8&pid=1-s2.0-S221287782400125X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Metabolic plasticity in a Pde6bSTOP/STOP retinitis pigmentosa mouse model following rescue\",\"authors\":\"Monika Ayten , Nundehui Díaz-Lezama , Hanaa Ghanawi , Felia C. Haffelder , Jacqueline Kajtna , Tobias Straub , Marco Borso , Axel Imhof , Stefanie M. Hauck , Susanne F. Koch\",\"doi\":\"10.1016/j.molmet.2024.101994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Retinitis pigmentosa (RP) is a hereditary retinal disease characterized by progressive photoreceptor degeneration, leading to vision loss. The best hope for a cure for RP lies in gene therapy. However, given that RP patients are most often diagnosed in the midst of ongoing photoreceptor degeneration, it is unknown how the retinal proteome changes as RP disease progresses, and which changes can be prevented, halted, or reversed by gene therapy.</p></div><div><h3>Methods</h3><p>Here, we used a <em>Pde6b</em>-deficient RP gene therapy mouse model and performed untargeted proteomic analysis to identify changes in protein expression during degeneration and after treatment.</p></div><div><h3>Results</h3><p>We demonstrated that <em>Pde6b</em> gene restoration led to a novel form of homeostatic plasticity in rod phototransduction which functionally compensates for the decreased number of rods. By profiling protein levels of metabolic genes and measuring metabolites, we observed an upregulation of proteins associated with oxidative phosphorylation in mutant and treated photoreceptors.</p></div><div><h3>Conclusion</h3><p>In conclusion, the metabolic demands of the retina differ in our <em>Pde6b</em>-deficient RP mouse model and are not rescued by gene therapy treatment. These findings provide novel insights into features of both RP disease progression and long-term rescue with gene therapy.</p></div>\",\"PeriodicalId\":18765,\"journal\":{\"name\":\"Molecular Metabolism\",\"volume\":\"88 \",\"pages\":\"Article 101994\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S221287782400125X/pdfft?md5=6010579f47431b45363c3e5b7663bbf8&pid=1-s2.0-S221287782400125X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221287782400125X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221287782400125X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
视网膜色素变性(RP)是一种遗传性视网膜疾病,其特点是进行性感光细胞变性,导致视力丧失。治愈视网膜色素变性症的最大希望在于基因治疗。然而,鉴于RP患者通常是在感光细胞不断变性的过程中被诊断出来的,因此确定视网膜蛋白质组是如何随着RP疾病的进展而变化的,并确定哪些变化可以通过基因疗法来预防、阻止或逆转是非常重要的。在这里,我们使用了 Pde6b 缺失的 RP 基因治疗小鼠模型,并证明了 Pde6b 基因的恢复会导致视杆细胞光传导中一种新形式的同态可塑性,从而在功能上补偿视杆细胞数量的减少。通过分析代谢基因的蛋白质水平和测量代谢物,我们观察到在突变体和接受治疗的感光体中,与氧化磷酸化相关的蛋白质上调。因此,在我们的 Pde6b 缺失型 RP 小鼠模型中,视网膜的新陈代谢需求是不同的,而且不会因基因治疗而得到缓解。这些发现为了解 RP 疾病进展和基因治疗长期挽救的特征提供了新的视角。
Metabolic plasticity in a Pde6bSTOP/STOP retinitis pigmentosa mouse model following rescue
Objective
Retinitis pigmentosa (RP) is a hereditary retinal disease characterized by progressive photoreceptor degeneration, leading to vision loss. The best hope for a cure for RP lies in gene therapy. However, given that RP patients are most often diagnosed in the midst of ongoing photoreceptor degeneration, it is unknown how the retinal proteome changes as RP disease progresses, and which changes can be prevented, halted, or reversed by gene therapy.
Methods
Here, we used a Pde6b-deficient RP gene therapy mouse model and performed untargeted proteomic analysis to identify changes in protein expression during degeneration and after treatment.
Results
We demonstrated that Pde6b gene restoration led to a novel form of homeostatic plasticity in rod phototransduction which functionally compensates for the decreased number of rods. By profiling protein levels of metabolic genes and measuring metabolites, we observed an upregulation of proteins associated with oxidative phosphorylation in mutant and treated photoreceptors.
Conclusion
In conclusion, the metabolic demands of the retina differ in our Pde6b-deficient RP mouse model and are not rescued by gene therapy treatment. These findings provide novel insights into features of both RP disease progression and long-term rescue with gene therapy.
期刊介绍:
Molecular Metabolism is a leading journal dedicated to sharing groundbreaking discoveries in the field of energy homeostasis and the underlying factors of metabolic disorders. These disorders include obesity, diabetes, cardiovascular disease, and cancer. Our journal focuses on publishing research driven by hypotheses and conducted to the highest standards, aiming to provide a mechanistic understanding of energy homeostasis-related behavior, physiology, and dysfunction.
We promote interdisciplinary science, covering a broad range of approaches from molecules to humans throughout the lifespan. Our goal is to contribute to transformative research in metabolism, which has the potential to revolutionize the field. By enabling progress in the prognosis, prevention, and ultimately the cure of metabolic disorders and their long-term complications, our journal seeks to better the future of health and well-being.